To assess the pharmacokinetics and safety and tolerability of efanesoctocog alfa (BIVV001)in Adults with type 2N and 3 von Willebrand disease (VWD)

Trial Identifier: PKM16978
Sponsor: Bioverativ, a Sanofi company
Start Date: May 2021
Primary Completion Date: December 2022
Study Completion Date: December 2022
Condition: Von Willebrand Disease (VWD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
France LILLE, France, 59037
France Nantes, France, 44093
United States, Iowa Iowa City, Iowa, United States, 52242
United States, Pennsylvania Pittsburgh, Pennsylvania, United States, 15213